Aldesleukin [1], myelotoxic substance ---> SmPC of [1] of eMC
Concurrent administration of medicinal products with hepatotoxic, nephrotoxic, myelotoxic, or cardiotoxic effects may increase the toxicity of Proleukin in these systems.
Aurothiomalate, myelotoxic substance
The co-administration may have an additive myelotoxic effect
Cytarabine, myelotoxic substance
The co-administration may cause myelotoxic interaction
Dacarbazine [1], myelotoxic substance ---> SmPC of [1] of eMC
In case of previous or concomitant treatment having adverse effects on the bone marrow (particularly cytostatic agents, irradiation) myelotoxic interactions are possible.
Daunorubicin [1], myelotoxic substance ---> SmPC of [1] of eMC
If patients were/are (pre)treated with medicinal products influencing the bone marrow function the possibility of a marked disorder of hematopoiesis should be borne in mind.
Epirubicin, myelotoxic substance
The possibility of marked haematopoietic disorders should be considered
Interleukin-2 [1], myelotoxic substance ---> SmPC of [1] of eMC
Concurrent administration of medicinal products with hepatotoxic, nephrotoxic, myelotoxic, or cardiotoxic effects may increase the toxicity of Proleukin in these systems.
Myelotoxic substance, methotrexate
The risk of marked haematopoietic disorders should be considered
Myelotoxic substance, pegylated liposomal doxorubicin [2] ---> SmPC of [2] of EMA
Caution must be exercised when giving doxorubicin with any other cytotoxic agents, especially myelotoxic agents, at the same time.
Myelotoxic substance, sulfasalazine
Leucopenia, anemia and/or thrombocytopenia may occur more frequent and intensive
Myelotoxic substance, thioguanine
The co-administration may increase the risk of bone marrow depression
Myelotoxic substance, thiotepa [2] ---> SmPC of [2] of EMA
The concomitant use of thiotepa and other myelosuppressive or myelotoxic agents may potentiate the risk of haematologic adverse reactions due to overlapping toxicity profiles of these medicinal products.
Myelotoxic substance, vinblastine
The co-administration may increase the risk of toxicity
Myelotoxic substance, vinorelbine [2] ---> SmPC of [2] of eMC
The combination of vinorelbine and other drugs with known bone marrow toxicity is likely to increase the myelosuppressive adverse reactions.